Hans-Peter Kiem

Trials

Studies that name Hans-Peter Kiem as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:54 UTC. Open this list on ClinicalTrials.gov

• Ph1
  NCT02378922 · Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

  Fred Hutchinson Cancer Center · withdrawn · AIDS-Related Hodgkin Lymphoma, AIDS-Related Non-Hodgkin Lymphoma, HIV Infection · principal investigator
• Ph1
  NCT01331018 · Gene Therapy for Fanconi Anemia

  Fred Hutchinson Cancer Center · terminated · Fanconi Anemia · principal investigator
• Ph1/Ph2
  NCT00669669 · O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas

  Fred Hutchinson Cancer Center · terminated · Glioblastoma, Gliosarcoma · principal investigator
• Ph2
  NCT00453388 · Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia

  Fred Hutchinson Cancer Center · completed · Acute Myeloid Leukemia in Remission, de Novo Myelodysplastic Syndrome, Fanconi Anemia · principal investigator
• Ph1
  NCT00317876 · Cyclophosphamide in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Fanconi's Anemia

  Fred Hutchinson Cancer Center · completed · Fanconi Anemia · principal investigator
• Ph1
  NCT00093743 · Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia

  Fred Hutchinson Cancer Center · completed · Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) · principal investigator
• Ph1/Ph2
  NCT00089037 · Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation

  Fred Hutchinson Cancer Center · completed · Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 05:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 13 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

• CD90-targeted nanoparticles for in vivo hematopoietic stem cell gene therapy
  R01HL173365 · NHLBI · FRED HUTCHINSON CANCER CENTER · fiscal years 2025 to 2026 · $756,008 awarded in 2026
  Same name and institution; not confirmed by an ID
• In vivo gene therapy for Fanconi anemia
  R01HL147324 · NHLBI · FRED HUTCHINSON CANCER CENTER · fiscal years 2020 to 2026 · $835,731 awarded in 2026
  Same name and institution; not confirmed by an ID
• In vivo gene therapy for hemoglobinopathies with multiplexed virus-like particles
  R01HL136135 · NHLBI · FRED HUTCHINSON CANCER CENTER · fiscal years 2017 to 2026 · $905,029 awarded in 2026
  Same name and institution; not confirmed by an ID
• In vivo HSC gene therapy using a multi-modular HDAd vector for HIV cure
  R01AI174304 · NIAID · UNIVERSITY OF WASHINGTON · fiscal years 2023 to 2026 · $1,553,325 awarded in 2026
  Same name and institution; not confirmed by an ID
• Cell Manipulation Tools
  U54DK106829 · NIDDK · FRED HUTCHINSON CANCER CENTER · fiscal years 2021 to 2024 · $225,250 awarded in 2024
  Same name and institution; not confirmed by an ID
• Development of 211Astatine-Conjugated Anti-CD45 Antibody-Based Conditioning for Hematopoietic Stem Cell Gene Therapy and Editing
  R01HL151765 · NHLBI · FRED HUTCHINSON CANCER CENTER · fiscal years 2020 to 2023 · $861,939 awarded in 2023
  Same name and institution; not confirmed by an ID
• Targeting a Novel Hematopoietic Stem Cell Population in Non-Human Primates for Effective and Sustained Gene Therapy
  R01AI135953 · NIAID · FRED HUTCHINSON CANCER CENTER · fiscal years 2018 to 2022 · $684,721 awarded in 2022
  Same name and institution; not confirmed by an ID
• Cell and Gene Therapy for HIV Cure
  UM1AI126623 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2016 to 2020 · $4,564,019 awarded in 2020
  Same name and institution; not confirmed by an ID
• Nongenotoxic conditioning to enhance stem cell engineering and virus-specific immunity in nonhuman primates
  U19AI149676 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2020 · $514,184 awarded in 2020
  Same name and institution; not confirmed by an ID
• Cell and Gene Therapy for Nonmalignant Blood Disorders
  P01HL122173 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2015 to 2019 · $2,423,242 awarded in 2019
  Same name and institution; not confirmed by an ID
• 2017 Conference on Cell and Gene Therapy for HIV CURE
  R13AI134409 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2017 · $25,000 awarded in 2017
  Same name and institution; not confirmed by an ID
• Engraftment and in vivo selection of HIV-protected stem cells
  R01HL116217 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2012 to 2017 · $523,418 awarded in 2017
  Same name and institution; not confirmed by an ID
• Evaluation of Pluripotent Stem Cell-Derived Blood Cells in Nonhuman Primate Model
  R01HL115128 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2013 to 2016 · $835,271 awarded in 2016
  Same name and institution; not confirmed by an ID
• CCR5 Targeting to Control HIV/SHIV to Nonhuman Primates
  U19AI096111 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2011 to 2015 · $520,756 awarded in 2015
  Same name and institution; not confirmed by an ID
• Cell-Based Secretion of Antiviral Molecules as a Treatment for HIV-AIDS
  R21AI110154 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2014 to 2015 · $222,367 awarded in 2015
  Same name and institution; not confirmed by an ID
• Core D: Vector Production
  P30DK056465 · NIDDK · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 1999 to 2014 · $177,106 awarded in 2014
  Same name and institution; not confirmed by an ID
• Development of safe and efficient gene therapy strategies for hemoglobinopathies
  R01HL098489 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2010 to 2013 · $669,194 awarded in 2013
  Same name and institution; not confirmed by an ID
• Development of Novel AIDS Gene Therapy Strategies in the Macaque SHIV Model
  R01AI080326 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2009 to 2012 · $564,464 awarded in 2012
  Same name and institution; not confirmed by an ID
• Hematopoietic Chemoprotection in Glioblastoma Patients
  R01CA114218 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2006 to 2011 · $439,580 awarded in 2011
  Same name and institution; not confirmed by an ID
• LAGLIDADG Delivery and Gene Repair in Hematopoietic Stem Cells (7 of 11)
  RL1HL092554 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2007 to 2011 · $607,698 awarded in 2011
  Same name and institution; not confirmed by an ID
• Gene Therapy in Hematopoietic Cells
  P01HL036444 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2003 to 2010 · $777,107 awarded in 2010
  Same name and institution; not confirmed by an ID
• Cord Blood Expansion and Transplantation in a Nonhuman Primate Model
  R01HL084345 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2006 to 2009 · $729,751 awarded in 2009
  Same name and institution; not confirmed by an ID
• Gene therapy for Fanconi anemia
  R01HL085693 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2006 to 2009 · $669,918 awarded in 2009
  Same name and institution; not confirmed by an ID
• Core--Hematopoietic Cell Transduction
  P30DK047754 · NIDDK · UNIVERSITY OF WASHINGTON · fiscal years 1999 to 2008 · $134,931 awarded in 2008
  Same name and institution; not confirmed by an ID
• Gene Transfer into Hematopoietic Stem Cells
  P01HL053750 · NHLBI · UNIVERSITY OF WASHINGTON · fiscal years 1999 to 2008 · $408,564 awarded in 2008
  Same name and institution; not confirmed by an ID
• MGMT-Mediated in vivo Selection in a Large Animal Model
  R01HL074162 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2003 to 2006 · $422,336 awarded in 2006
  Same name and institution; not confirmed by an ID
• Gene Therapy for Patients with Fanconi Anemia
  U01HL066947 · NHLBI · UNIVERSITY OF WASHINGTON · fiscal years 2000 to 2005 · $322,667 awarded in 2005
  Same name and institution; not confirmed by an ID
• Hematopoietic Potential of Muscle-Derived Cells
  R21DK063324 · NIDDK · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2003 to 2004 · $173,000 awarded in 2004
  Same name and institution; not confirmed by an ID
• IN VIVO SELECTION FOR STEM CELL GENE THERAPY
  R21DK053265 · NIDDK · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 1997 to 1998 · $172,879 awarded in 1998
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Cancer Center Administration
  P30CA015704 · NCI · FRED HUTCHINSON CANCER CENTER · PI WENDY LAW · fiscal years 2018 to 2026
  Named on NCT02378922, NCT00453388, NCT00093743